Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy Medicine
Phase I Results for Ragweed Immunotherapy Presented
March 31st, 2000
Dynavax Technologies Corp. announced the presentation of data from a Phase I study of AIC, a proprietary conjugate of purified ragweed allergen (Amb a 1) to an immunostimulatory polynucleotide DNA sequence (ISS), at the 56th annual American Academy of Allergy, Asthma and Immunology Meeting, held in San Diego, California, during March 2000. The Phase I open-label study, presented by principal investigator, Peter S. Creticos, MD, Johns Hopkins University, Baltimore, Maryland, compared the skin test responses of six ragweed allergic subjects to AIC versus a licensed ragweed extract. The skin test allergic response to AIC was significantly less than...
Source: Drug Week (2000-03-31)
|
